Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xencor Inc (XNCR)

Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,120,423
  • Shares Outstanding, K 71,410
  • Annual Sales, $ 110,490 K
  • Annual Income, $ -232,620 K
  • EBIT $ -120 M
  • EBITDA $ -121 M
  • 60-Month Beta 0.96
  • Price/Sales 10.21
  • Price/Cash Flow N/A
  • Price/Book 1.80

Options Overview Details

View History
  • Implied Volatility 211.32% (-45.72%)
  • Historical Volatility 58.49%
  • IV Percentile 72%
  • IV Rank 40.81%
  • IV High 440.78% on 09/10/25
  • IV Low 53.12% on 08/18/25
  • Expected Move (DTE 28) 2.98 (19.13%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 6
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 1,324
  • Open Int (30-Day) 1,356
  • Expected Range 12.58 to 18.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.64
  • Number of Estimates 7
  • High Estimate -0.10
  • Low Estimate -0.95
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.38 +1.11%
on 11/21/25
18.69 -16.80%
on 12/05/25
-0.22 (-1.40%)
since 11/19/25
3-Month
10.05 +54.80%
on 09/22/25
18.69 -16.80%
on 12/05/25
+5.26 (+51.12%)
since 09/19/25
52-Week
6.92 +124.71%
on 08/11/25
25.02 -37.85%
on 12/20/24
-8.46 (-35.24%)
since 12/19/24

Most Recent Stories

More News
Xencor Announces Extension of U.S. Patent Term on Certain Xtendâ„¢ Antibodies

-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty...

XNCR : 15.55 (-0.89%)
Xencor to Participate at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will...

XNCR : 15.55 (-0.89%)
Xencor: Q3 Earnings Snapshot

Xencor: Q3 Earnings Snapshot

XNCR : 15.55 (-0.89%)
Xencor Reports Third Quarter 2025 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third...

XNCR : 15.55 (-0.89%)
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion...

XNCR : 15.55 (-0.89%)
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday,...

XNCR : 15.55 (-0.89%)
Xencor (XNCR) Gets a Buy from Cantor Fitzgerald

In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Xencor, with a price target of $40.00. The company’s shares opened today at $13.95.Elevate Your Investing...

XNCR : 15.55 (-0.89%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.6300 (+3.82%)
AVAI : 0.3394 (+0.95%)
DNLI : 16.85 (+0.48%)
EDIT : 2.34 (-0.43%)
XNCR : 15.55 (-0.89%)
Bank of America Securities Reaffirms Their Hold Rating on Xencor (XNCR)

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Xencor today and set a price target of $14.00. The company’s shares closed yesterday at $13.96.Elevate Your Investing Strategy:...

XNCR : 15.55 (-0.89%)
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

-- Management to host webcast and conference call on Friday, October 24, 2025 --

XNCR : 15.55 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 16.55
2nd Resistance Point 16.33
1st Resistance Point 15.94
Last Price 15.55
1st Support Level 15.34
2nd Support Level 15.12
3rd Support Level 14.73

See More

52-Week High 25.02
Fibonacci 61.8% 18.11
Fibonacci 50% 15.97
Last Price 15.55
Fibonacci 38.2% 13.83
52-Week Low 6.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar